Hostname: page-component-76fb5796d-9pm4c Total loading time: 0 Render date: 2024-04-25T22:42:27.135Z Has data issue: false hasContentIssue false
  • English
  • Français

Economic evaluations of leukemia: A review of the literature

Published online by Cambridge University Press:  18 January 2007

Frida Kasteng ,
Patrik Sobocki ,
Christer Svedman  and
Jonas Lundkvist
Frida Kasteng
Affiliation:
European Health Economics
Patrik Sobocki
Affiliation:
Karolinska InstituteandEuropean Health Economics
Christer Svedman
Affiliation:
Karolinska Hospital
Jonas Lundkvist
Affiliation:
Karolinska InstituteandEuropean Health Economics
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: Leukemia, together with lymphoma and multiple myeloma, are hematological malignancies, malignancies of the blood-forming organs. There are four major types of leukemia: acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL). There is a growing amount of literature of the health economic aspects of leukemia. However, no comprehensive review is yet performed on the health economic evidence for the disease. Hence, our aim was to review and analyze the existing literature on economic evaluations of the different types of leukemia.

Methods: A systematic literature search used electronic databases to identify published cost analyses and economic evaluations of leukemia treatments. After reviewing all identified studies, sixty studies were considered relevant for the purpose of the review.

Results: The identified studies were published after 1990, with a few exceptions. Many of the identified economic evaluations in leukemia, particularly for ALL and AML, may be defined as cost-minimization analyses, where only the costs of different treatment strategies are compared. In CML, a new treatment, imatinib, was introduced in 2001 and several cost-effectiveness analyses have since then been conducted comparing imatinib with previous first line treatments.

Conclusions: This review indicates that there is a shortage of cost-effectiveness information in leukemia. The introduction of new therapies will stress the need for new economic evaluations in this group of diseases. More information about the total costs, that is, including indirect costs, and quality of life effects would be valuable in future evaluations in leukemia.

Keywords

LeukemiaCostHematologicalCost-effectiveness
Type
GENERAL ESSAYS
Information
International Journal of Technology Assessment in Health Care , Volume 23 , Issue 1 , January 2007 , pp. 43 - 53
Copyright
© 2007 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Andritsos L, Khoury H. 2002 Chronic lymphocytic leukemia. Curr Treat Options Oncol. 3: 225– 231.Google Scholar
Barr R, Furlong W, Henwood J, et al. 1996 Economic evaluation of allogeneic bone marrow transplantation: A rudimentary model to generate estimates for the timely formulation of clinical policy. J Clin Oncol. 14: 1413– 1420.Google Scholar
Bassan R, Lerede T, Di Bona E, et al. 1997 Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: Effects, role of patient pretreatment characteristics, and costs. Leuk Lymphoma. 26: 153– 161.Google Scholar
Beck JR, Guilhot J, Giles FJ, et al. 2001 Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia. Leuk Lymphoma. 41: 117– 124.Google Scholar
Bennett C.L, Hynes D, Godwin J, et al. 2001 Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): Estimates from a Southwest Oncology Group clinical trial. Cancer Invest. 19: 603– 610.Google Scholar
Bennett CL, Schumock GT. 2003 Cost analyses of adjunct colony stimulating factors for older patients with acute myeloid leukaemia: Can they improve clinical decision making? Drugs Aging. 20: 479– 483.Google Scholar
Bennett CL, Stinson TJ, Lane D, et al. 2000 Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: A case for prospective economic analysis in cooperative group trials. Med Pediatr Oncol. 34: 92– 96.Google Scholar
Bennett CL, Stinson TJ, Tallman MS, et al. 1999 Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490). Ann Oncol. 10: 177– 182.Google Scholar
Berman E, Little C, Teschendorf B, Jones M, Heller G. 2002 Financial analysis of patients with newly diagnosed acute myelogenous leukemia on protocol or standard therapy. Cancer. 95: 1064– 1070.Google Scholar
Blaise D, Kuentz M, Fortanier C, et al. 2000 Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 18: 537– 546.Google Scholar
Briggs AH, O'Brien BJ. 2001 The death of cost-minimization analysis? Health Econ. 10: 179– 184.Google Scholar
Clavio M, Quintino S, Masoudi B, et al. 2001 Cost of de novo acute myeloid leukemia induction therapy in adults: Analysis of EORTC-GIMEMA AML10 and FLANG regimens. J Exp Clin Cancer Res. 20: 165– 173.Google Scholar
Cordonnier C, Maury S, Esperou H, et al. 2005 Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Bone Marrow Transplant. 36: 649– 654.Google Scholar
Cripe LD, Hinton S. 2000 Acute myeloid leukemia in adults. Curr Treat Options Oncol. 1: 9– 17.Google Scholar
Dalziel K, Round A, Garside R, Stein K. 2005 Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics. 23: 515– 526.Google Scholar
Delorme J, Badin S, Le Corroller AG, et al. 2003 Economic evaluation of recombinant human granulocyte colony-stimulating factor in very high-risk childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 25: 441– 447.Google Scholar
Dufoir T, Saux MC, Terraza B, et al. 1992 Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. Bone Marrow Transplant. 10: 323– 329.Google Scholar
Fisher AJ. 2001. Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia–Fludarabine Annex: Cost-effectiveness. National Institute for Health and Clinical Excellence;
Gaynon PS, Bostrom BC, Hutchinson RJ, et al. 2001 Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies. J Clin Oncol. 19: 1916– 1925.Google Scholar
GLOBOCAN 2002. International Agency for Research on Cancer.
Gordois A, Scuffham P, Warren E, Ward S. 2003 Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. Br J Cancer. 89: 634– 640.Google Scholar
Gratwohl A, Baldomero H, Passweg J, et al. 2003 Hematopoietic stem cell transplantation for hematological malignancies in Europe. Leukemia. 17: 941– 959.Google Scholar
Hancock S, et al. 2003. Fludarabine as first line therapy for chronic lymphocytic leukemia. West Midland Health Technology Assessment Collaboration
HCUPnet: HCUP Nationwide Inpatient Sample (NIS)2002. Agency for Healthcare Cost and Utilization Project.
Hyde C, Wake B, Bryan S, et al. 2002 Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: A technology assessment. Health Technol Assess. 6: 1– 89.Google Scholar
Kattan MW, Inoue Y, Giles FJ, et al. 1996 Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med. 125: 541– 548.Google Scholar
Kurre HA, Ettinger AG, Veenstra DL, et al. 2002 A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: The Children's Cancer Group study (CCG-1962). J Pediatr Hematol Oncol. 24: 175– 181.Google Scholar
Lang K, Earle CC, Foster T, et al. 2005 Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging. 22: 943– 955.Google Scholar
Lee SJ, Anasetti C, Kuntz KM, et al. 1998 The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood. 92: 4047– 4052.Google Scholar
Lee SJ, Klar N, Weeks JC, Antin JH. 2000 Predicting costs of stem-cell transplantation. J Clin Oncol. 18: 64– 71.Google Scholar
Liberato NL, Quaglini S, Barosi G. 1997 Cost-effectiveness of interferon alfa in chronic myelogenous leukemia. J Clin Oncol. 15: 2673– 2682.Google Scholar
Lobo PJ, Powles RL, Hanrahan A, Reynold DK. 1991 Acute myeloblastic leukaemia–a model for assessing value for money for new treatment programmes. BMJ. 302: 323– 326.Google Scholar
Luce BR, Singer JW, Weschler JM, et al. 1994 Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer: An economic analysis of a randomised, double-blind, placebo-controlled trial. Pharmacoeconomics. 6: 42– 48.Google Scholar
Madero L, Gonzalez Vincent M, Ramirez M, et al. 2000 Clinical and economic comparison of allogeneic peripheral blood progenitor cell and bone marrow transplantation for acute lymphoblastic leukemia in children. Bone Marrow Transplant. 26: 269– 273.Google Scholar
Marie JP, Wdowik T, Bisserbe S, Zittoun R. 1992 Cost of complete remission induction in acute myeloblastic leukemia: Evaluation of the cost-effectiveness of a new drug. Leukemia. 6: 720– 722.Google Scholar
Mason JM, Drummond MF, Bosanquet AG, Sheldon TA. 1999 The DiSC assay. A cost-effective guide to treatment for chronic lymphocytic leukemia? Int J Technol Assess Health Care. 15: 173– 184.Google Scholar
Menzin J, Lang K, Earle CC, Glendenning A. 2004 Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: A population-based analysis. Drugs Aging. 21: 737– 746.Google Scholar
Menzin J, Lang K, Earle CC, Kerney D, Mallick R. 2002 The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 162: 1597– 1603.Google Scholar
Messori A. 1998 Cost-effectiveness of interferon in chronic myeloid leukaemia: Analysis of four clinical studies. Ann Oncol. 9: 389– 396.Google Scholar
Messori A, Bosi A, Bacci S, et al. 1999 Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia. Gruppo Italiano Trapianto di Midollo Osseo. Bone Marrow Transplant. 23: 489– 495.Google Scholar
Mishra V, Vaaler S, Brinch L. 2001 A prospective cost evaluation related to allogeneic haemopoietic stem cell transplantation including pretransplant procedures, transplantation and 1 year follow-up procedures. Bone Marrow Transplant. 28: 1111– 1116.Google Scholar
2005. National Cancer Institute–Childhood Acute Lymphoblastic Leukemia (PDQ): Treatment. National Cancer Institute
2006. NCCN Clinical Practice Guidelines in Oncology–Acute Myeloid Leukemia. National Comprehensive Cancer Network Version 1.
2006. NCCN Clinical Practice Guidelines in Oncology–Chronic Myelogenous Leukemia. National Comprehensive Cancer Network; Version 1.
2006. NCCN Clinical Practice Guidelines in Oncology–Non-Hodgkin's Lymphoma. National Comprehensive Cancer Network; Version 2.
NHS Economic Evaluation Database, Health Technology Assessment Database. Centre for Reviews and Dissemination, University of York.
O'Brien SG, Guilhot F, Larson RA, et al. 2003 Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 348: 994– 1004.Google Scholar
Ozer H, Golomb HM, Zimmerman H, Spiegel RJ. 1989 Cost-benefit analysis of interferon alfa-2b in treatment of hairy cell leukemia. J Natl Cancer Inst. 81: 594– 602.Google Scholar
Pashko S, Jacobs J, Santorsa J. 1991 The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia. Clin Ther. 13: 353– 360.Google Scholar
Peters BG, Goeckner BJ, Ponzillo JJ, Velasquez WS, Wilson AL. 1995 Pegaspargase versus asparaginase in adult ALL: A pharmacoeconomic assessment. Formulary. 30: 388– 393.Google Scholar
Rahiala J, Riikonen P, Kekalainen L, Perkkio M. 2000 Cost analysis of the treatment of acute childhood lymphocytic leukaemia according to Nordic protocols. Acta Paediatr. 89: 482– 487.Google Scholar
Reed SD, Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA. 2004 Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 101: 2574– 2583.Google Scholar
Ries LAG, Harkins D, Krapcho M, et al. SEER cancer statistics review. 1975-2003. National Cancer Institute; 2005.
Rosenman MB, Vik T, Hui SL, Breitfeld PP. 2005 Hospital resource utilization in childhood cancer. J Pediatr Hematol Oncol. 27: 295– 300.Google Scholar
Skrepnek GH, Ballard EE. 2005 Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: A decision-analytic approach. Pharmacotherapy. 25: 325– 334.Google Scholar
Stalfelt AM, Brodin H. 1994 Costs over time in conventional treatment of acute myeloid leukaemia. A study exploring changes in treatment strategies over two decades. J Intern Med. 236: 401– 409.Google Scholar
Stalfelt AM, Brodin H, Wadman B. 1994 Cost analysis of different phases of acute myeloid leukaemia. Leuk Res. 18: 783– 790.Google Scholar
Standaert B, Goldstone J, Lu ZJ, Erder MH, Yin JL. 2002 Economic analysis of filgrastim use for patients with acute myeloid leukaemia in the UK: A comparison of collection methods of resource use data. Pharmacoeconomics. 20: 665– 674.Google Scholar
Tennvall GR, Persson U, Nilsson B. 1994 The economic costs of acute myeloid leukemia in Sweden. Int J Technol Assess Health Care. 10: 683– 694.Google Scholar
Uyl-de-Groot CA, Gelderblom-den Hartog J, Huijgens PC, Willemze R, van Ineveld BM. 2001 Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the Netherlands. J Hematother Stem Cell Res. 10: 187– 192.Google Scholar
Uyl-de-Groot CA, Lowenberg B, Vellenga E, et al. 1998 Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. Br J Haematol. 100: 629– 636.Google Scholar
Uyl-de-Groot CA, Okhuijsen SY, Hagenbeek A, et al. 1995 Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands. Bone Marrow Transplant. 15: 605– 610.Google Scholar
van Agthoven M, Groot MT, Verdonck LF, et al. 2002 Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant. 30: 243– 251.Google Scholar
Warren E, Ward S, Gordois A, Scuffham P. 2004 Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase. Clin Ther. 26: 1924– 1933.Google Scholar
Weeks JC, Tierney MR, Weinstein MC. 1991 Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med. 325: 81– 86.Google Scholar
Welch HG, Larson EB. 1989 Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med. 321: 807– 812.Google Scholar
Vicent MG, Madero L, Chamorro L, Madero R, Diaz MA. 2001 Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies. Haematologica. 86: 1087– 1094.Google Scholar
Williams JP, Handler HL. 2000 Antibody-targeted chemotherapy for the treatment of relapsed acute myeloid leukemia. Am J Manag Care. 6 (Suppl): S975– S985.Google Scholar
von Stackelberg A, Karatchunsky A, Kudrjashova J, et al. 1999 Toxicity, supportive care and costs of two chemotherapy protocols for treatment of childhood ALL in Russia: BFM 90m and MB 91. Eur J Cancer. 35: 1349– 1355.Google Scholar
Woronoff-Lemsi MC, Witz F, Arveux P, Cahn JY, Harousseau JL. 2001 [Cost effectiveness of GM-CSF in the treatment of acute myeloblastic leukemia in aged patients: Protocol of GOELAM Sa3]. Therapie. 56: 131– 133.Google Scholar